|
|
A novel mutation W257R in GCK gene discovered from a Chinese patient with maturity onset diabetes of the young |
HONG Pingping( ),GUO Bingjie,LIN Li,LIN Xihua,ZHOU Jiaqiang*( ) |
Department of Endocrinology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou 310016, China |
|
|
Abstract Maturity onset diabetes of the young (MODY) is a monogenic autosomal dominant inherited disease. Its clinical manifestations are asymptomatic with slightly elevated fasting blood glucose and few complications. This paper reports a novel mutation W257R in glucokinase (GCK) gene from a Chinese patient with MODY. Heterozygous mutation c.769T>C (p.W257R) in exon 7 of GCK gene (Chr744187343) was found in the proband, her father and brother. This W257R mutation was first reported in Chinese population.
|
Received: 30 November 2018
Published: 24 July 2019
|
|
Corresponding Authors:
ZHOU Jiaqiang
E-mail: 525192665@qq.com;zjq8866@zju.edu.cn
|
葡萄糖激酶W257R突变致青少年发病的成人型糖尿病一家系分析
青少年发病的成人型糖尿病(MODY)是一类以常染色体显性模式遗传的单基因疾病,临床表现以无症状、轻度空腹血糖升高为特征,很少出现糖尿病并发症。本文报道一例中国人群中葡萄糖激酶(GCK)基因新发W257R突变所致的MODY。在先证者及父亲、弟弟中均发现GCK基因(Chr744187343)第7号外显子的杂合突变c.769T>C(p.W257R)。该家系中W257R突变在中国人群中为首发。
关键词:
基因, 显性,
染色体, 人,
突变,
葡糖激酶/遗传学,
糖尿病, 2型/遗传学,
系谱,
中国,
病例报告
|
|
[1] |
GARDNER D S , TAI E S . Clinical features and treatment of maturity onset diabetes of the young(MODY)[J]. Diabetes Metab Syndr Obes, 2012, 5 101- 108
|
|
|
[2] |
SHIELDS B M , HICKS S , SHEPHERD M H et al. Maturity-onset diabetes of the young(MODY):how many cases are we missing?[J]. Diabetologia, 2010, 53 (12): 2504- 2508
doi: 10.1007/s00125-010-1799-4
|
|
|
[3] |
PRUDENTE S , JUNGTRAKOON P , MARUCCI A et al. Loss-of-function mutations in APPL1 in familial diabetes mellitus[J]. Am J Hum Genet, 2015, 97 (1): 177- 185
doi: 10.1016/j.ajhg.2015.05.011
|
|
|
[4] |
FIRDOUS P , NISSAR K , ALI S et al. Genetic testing of maturity-onset diabetes of the young current status and future perspectives[J]. Front Endocrinol(Lausanne), 2018, 9 253
doi: 10.3389/fendo.2018.00253
|
|
|
[5] |
BISHAY R H , GREENFIELD J R . A review of maturity onset diabetes of the young(MODY) and challenges in the management of glucokinase-MODY[J]. Med J Aust, 2017, 207 (5): 223
doi: 10.5694/mja2.2017.207.issue-5
|
|
|
[6] |
FROGUEL P , VAXILLAIRE M , SUN F et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus[J]. Nature, 1992, 356 (6365): 162- 164
doi: 10.1038/356162a0
|
|
|
[7] |
MA Y , HAN X , ZHOU X et al. A new clinical screening strategy and prevalence estimation for glucokinase variant-induced diabetes in an adult Chinese population[J]. Genet Med, 2019, 21 (4): 939- 947
doi: 10.1038/s41436-018-0282-3
|
|
|
[8] |
MCDONALD T J , ELLARD S . Maturity onset diabetes of the young:identification and diagnosis[J]. Ann Clin Biochem, 2013, 50 (Pt 5): 403- 415
|
|
|
[9] |
CHAKERA A J , STEELE A M , GLOYNA L et al. Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation[J]. Diabetes Care, 2015, 38 (7): 1383- 1392
doi: 10.2337/dc14-2769
|
|
|
[10] |
OSBAK K K , COLCLOUGH K , SAINT-MARTIN C et al. Update on mutations in glucokinase(GCK), which cause maturity-onset diabetes of the young, permanent neonatal diabetes, and hyperinsulinemic hypoglycemia[J]. Hum Mutat, 2009, 30 (11): 1512- 1526
doi: 10.1002/humu.v30:11
|
|
|
[11] |
GEORGE D C , CHAKRABORTY C , HANEEFS A et al. Evolution-and structure-based computational strategy reveals the impact of deleterious missense mutations on MODY 2(maturity-onset diabetes of the young, type 2)[J]. Theranostics, 2014, 4 (4): 366- 385
doi: 10.7150/thno.7473
|
|
|
[12] |
MATSCHINSKY F , LIANG Y , KESAVAN P et al. Glucokinase as pancreatic beta cell glucose sensor and diabetes gene[J]. J Clin Invest, 1993, 92 (5): 2092- 2098
doi: 10.1172/JCI116809
|
|
|
[13] |
GLASER B , KESAVAN P , HEYMAN M et al. Familial hyperinsulinism caused by an activating glucokinase mutation[J]. N Engl J Med, 1998, 338 (4): 226- 230
doi: 10.1056/NEJM199801223380404
|
|
|
[14] |
BYRNE M M , STURIS J , CLéMENT K et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations[J]. J Clin Invest, 1994, 93 (3): 1120- 1130
doi: 10.1172/JCI117064
|
|
|
[15] |
STRIDE A , SHIELDS B , GILL-CAREY O et al. Cross-sectional and longitudinal studies suggest pharmacological treatment used in patients with glucokinase mutations does not alter glycaemia[J]. Diabetologia, 2014, 57 (1): 54- 56
doi: 10.1007/s00125-013-3075-x
|
|
|
[16] |
SHEPHERD M H , SHIELDS B M , HUDSON M et al. A UK nationwide prospective study of treatment change in MODY:genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin[J]. Diabetologia, 2018, 61 (12): 2520- 2527
doi: 10.1007/s00125-018-4728-6
|
|
|
[17] |
STEELE A M , SHIELDS B M , WENSLEY K J et al. Prevalence of vascular complications among patients with glucokinase mutations and prolonged, mild hyperglycemia[J]. JAMA, 2014, 311 (3): 279- 286
doi: 10.1001/jama.2013.283980
|
|
|
[18] |
COSTA A , BESCíS M , VELHO G et al. Genetic and clinical characterisation of maturity-onset diabetes of the young in Spanish families[J]. Eur J Endocrinol, 2000, 142 (4): 380- 386
|
|
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|